Bill Haney adds a matching $100,000 contribution to Kristen Hege's adventurous fundraiser backing women scientists

Kristen Hege’s campaign to raise $500,000 to encourage the recruitment of women scientists into the Penn lab of Bruce Levine and Carl June is gaining …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Bill Haney adds a matching $100,000 contribution to Kristen Hege's adventurous fundraiser backing women scientists

This article is available only to Premium subscribers

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Bill Haney adds a match­ing $100,000 con­tri­bu­tion to Kris­ten Hege's ad­ven­tur­ous fundrais­er back­ing women sci­en­tists

This article is available only to Premium subscribers

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Bill Haney adds a matching $100,000 contribution to Kristen Hege's adventurous fundraiser backing women scientists

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus